AUG 25, 2019 8:24 PM PDT

Unprecedented Therapeutic Found Effective for Blood Cancer

WRITTEN BY: Nouran Amin

According to the findings of a clinical trial, scientists at Mt. Sinai have found a new therapeutic effective for patients with a particular type of bone marrow cancer. The cancer is known to be resistant to several standard therapeutics. Findings were published in the The New England Journal of Medicine and involves testing the drug selinexor with dexamethasone--a combination that treated the cancer in a quarter of patients where two of these patients went into complete remission.

In cancer cell biology, proteins and messenger RNAs play a critical role in cancer growth. Selinexor was found to inhibit the export of protein and messenger RNAs from the nucleus of the cancer cell to the cytoplasm resulting in cancer cell death.

"This study proved that a novel, first-in-class drug with a new mechanism of action can kill a patient's cancer cells," said the study's senior author, Sundar Jagannath, MBBS, Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute at Mount Sinai. "This proved that the drug worked in patients who had exhausted every other treatment and who would have been placed on hospice care otherwise."

Patients enrolled in the clinical trial, known as the STORM Part 2 Study, who took selinexor and dexamethasone, saw a response within one or two months. Even though no toxicity was present, patients did experience low blood count, nausea, vomiting, and lack of appetite or fatigue.

"This study is meaningful for patients with multiple myeloma who haven't had success on multiple other therapies," said the study's first author Ajai Chari, MD, Director of Clinical Research in the Multiple Myeloma Program at The Tisch Cancer Institute at Mount Sinai. "An increasing number of patients have resistance to the standard drugs used in the treatment of multiple myeloma, and the overall survival in these patients is short, sometimes less than three months."

Selinexor has been approved by the FDA for patients resistant to multiple therapies and the drug is being studied for multiple myeloma as well as in other malignancies such lymphoma and ovarian cancer.

In the Tisch Cancer Institute at Mount Sinai, the study brings a major milestone in myeloma research.

"The Center of Excellence for Multiple Myeloma is part of The Tisch Cancer Institute and uses the most advanced diagnostic and treatment approaches within state-of-the-art facilities of a National Cancer Institute-designated cancer center," said Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute, Chair of Oncological Sciences, and Ward-Coleman Professor in Cancer Research of the Icahn School of Medicine at Mount Sinai. "Coordinated care teams include experts from the Bone Marrow Transplant Program, pathology, radiology, immunology, genomics, infectious diseases, orthopedic surgery, cardiology, and nephrology, and patients will have broad access to comprehensive supportive services, including from social workers, financial counselors, and clergy."

Source: The Mount Sinai School of Medicine

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Promising Treatment for Dementia: Antibiotics
A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to resear...
FEB 08, 2020
Cancer
FEB 08, 2020
Magic mushrooms help cancer patients' depression
A follow-up to a study originally published in the Journal of Psychopharmacology in 2016 reports the long-term benefits of a one-time, single-dose tre...
FEB 12, 2020
Drug Discovery & Development
FEB 12, 2020
Does Traditional Chinese Medicine Work Against Coronavirus?
Over 45,000 cases of Wuhan Coronavirus have been reported globally, alongside over 1,100 deaths. Although over 4,700 people are said to have recovered from...
FEB 10, 2020
Drug Discovery & Development
FEB 10, 2020
Drug Prevents Coronavirus in Monkeys
An antiviral drug successfully prevented Middle East respiratory syndrome coronavirus (MERS-CoV) in infected rhesus macaques. The drug, Remdesivir, was adm...
MAR 07, 2020
Drug Discovery & Development
MAR 07, 2020
Single Trip on Magic Mushrooms Boosts Mindfulness
According to new research, a single trip from magic mushrooms is enough for people to experience long-term increases in mindfulness and openness. Mindfulne...
MAR 07, 2020
Drug Discovery & Development
MAR 07, 2020
Do Surgical Masks Really Prevent the Spread of COVID-19?
As COVID-19 has spread around the world, there has been a global run on surgical masks. This has led some governments, such as that in India, to ban the ex...
Loading Comments...